NHS vs private GLP-1 access in the UK

At a glance

The NHS route

How it works

Wegovy (NICE TA875) and Mounjaro (NICE TA1026) are NHS-recommended for weight management, restricted to specialist weight-management services. The pathway typically:

1. GP discussion and BMI / comorbidity check.
2. Referral to a Tier 3 or Tier 4 weight-management service.
3. Specialist clinical assessment.
4. Prescription, titration, and follow-up within the specialist service.
5. Time-limited recommendation (TA875 caps at two years).

Pros

• Free at the point of use.
• Structured clinical pathway with built-in follow-up.
• UK regulated supply chain throughout.

Cons

• Eligibility criteria are firm. Many patients don’t meet them.
• Waiting lists for specialist services are often long.
• Local availability varies — your ICB / health board determines access.
• Time-capped use (TA875).

The private route

How it works

A GMC-registered prescriber assesses you, prescribes if clinically appropriate, and a GPhC-registered pharmacy dispenses. The clinic is typically online; some operate from premises.

Pros

• Faster — initial consultation is usually within days.
• Often broader eligibility — assessment is clinical rather than to a NICE template.
• UK regulated supply chain throughout if the clinic is lawful.

Cons

• You pay — both for the consultation and the medicine, monthly.
• Quality varies enormously. Real clinics use GMC-registered prescribers and named GPhC pharmacies; superficially-similar shopfronts use neither. See how to check a UK online pharmacy.
• Supply gaps still affect private clinics during shortages.

The wrong answer — grey-market supply

The third option you’ll see online is buying GLP-1 from an unlicensed source — non-UK pharmacy, peer-to-peer, ‘research-grade semaglutide’ vials. This route is:

• Unlawful. POM supply without a prescription is a criminal offence.
• Frequently counterfeit. The February 2026 Mounjaro 15 mg KwikPen alert was about this route.
• Outside the regulated quality chain. No PIL, no batch testing you can rely on, no recall mechanism, no licensed prescriber accountable.
• No adverse-event safety net. Yellow Card can log what happened to you; it can’t fix what happened to you.

Don’t. If NHS access is slow and private cost is prohibitive, the right move is to talk to your GP about interim options — not to go grey-market.

How to decide

• If you meet NICE criteria comfortably: NHS referral first. Use the wait as a chance to start lifestyle changes that increase the medicine’s effect.
• If you’re borderline on NICE criteria: GP discussion. A specialist service may still accept the referral; if not, a private consultation can confirm the clinical picture.
• If you don’t meet NICE criteria but have clinical reasons: Private route with a lawful clinic. Don’t self-prescribe via grey market.
• If cost is the only barrier: Patience and persistence with the NHS pathway, plus genuine lifestyle engagement, may be the right answer.